ClinicalTrials.gg
RecruitingNCT06499805Updated Nov 2, 2026

Barriers and Facilitators to OTC Hearing Aids Success

An interventional study of Audiologist-based fitting and Over-the-counter fitting in Hearing Loss, Sensorineural and Presbycusis, sponsored by Yu-Hsiang Wu. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Primary conditionPresbycusisRegistry: Hearing Loss, SensorineuralReclassifiedWhy we changed it
Registry
Hearing Loss, Sensorineural — the first condition term the registry derived for this study.
ClinicalTrials.gg
Presbycusis
Why
  1. The study's listed conditions name Presbycusis, a narrower term within Hearing Loss, Sensorineural.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Yu-Hsiang Wu · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Non-randomized
Ages
18 Years to 89 Years
Sex
All
01

Study summary

Hearing aids can improve hearing, communication, and overall quality of life for people with hearing loss. However, not many people use hearing aids. A common reason is that hearing aids are expensive and hard to get. The traditional way to get hearing aids involves multiple visits to licensed audiologists for identifying hearing loss, customizing the aids, and ongoing maintenance. This traditional method is called the AUD pathway.

Over-the-counter (OTC) hearing aids offer a different approach. They aim to make hearing aids more affordable and accessible, encouraging earlier use. In the OTC pathway, users diagnose their own hearing loss and fit and program the hearing aids themselves. Little is known about long-term effects of OTC hearing aids on users.

This study aims to compare the experiences of people who choose the OTC pathway with those who choose the AUD pathway. It takes place in two locations: Iowa City, IA, and Nashville, TN. Participants, who have mild-to-moderate hearing loss, choose their preferred pathway and are followed for 12 months. In the OTC pathway, participants buy their hearing aids directly from OTC companies or retailers. In the AUD pathway, prescription hearing aids and fitting services are provided by audiology clinics at the University of Iowa and Vanderbilt University Medical Center.

Participants are contacted 1, 6, and 12 months after starting to use their hearing aids. Researchers measure their satisfaction about hearing aids and other outcomes. If participants stop using their hearing aids, researchers assess their engagement with post-amplification hearing care. The results from both pathways are then compared.

Read the detailed description

Although hearing aids (HAs) can improve hearing ability, communication, social and emotional function, and quality of life for people with hearing loss, the adoption rate of HAs is low. A commonly reported barrier to HA uptake is that HAs are not affordable or accessible under the traditional service delivery model, which requires multiple visits to licensed audiologists for identification of hearing loss, customization of the HAs, and continual maintenance and fine-tuning. This hearing healthcare pathway is referred to as the AUD pathway. As an alternative, over-the-counter (OTC) HAs aim to promote earlier HA adoption and improve HA affordability and accessibility. In this healthcare pathway, referred to as the OTC pathway, users self-diagnose hearing loss and fit and program their OTC HAs. Although prior research has supported the feasibility of HA self-fitting and the OTC service-delivery model, little is known about how the OTC pathway impacts users' long-term well-being.

The goal of this study is to characterize the patient journey of individuals who opt for the OTC pathway in comparison to those who select the AUD pathway. The study is a two-site (Iowa City, IA, and Nashville, TN) longitudinal study in which participants choose their preferred healthcare pathways (OTC vs. AUD), and their HA outcomes are tracked for 12 months. Adults with bilateral mild-to-moderate hearing loss are recruited from the community. Upon entering the study, participants choose their preferred pathway and then proceed with the purchase of HAs. In the OTC pathway, participants purchase their chosen OTC HAs directly from OTC companies or retailers. In the AUD pathway, prescription HAs and fitting services are offered by the audiology clinics at the University of Iowa and Vanderbilt University Medical Center. Participants are contacted 1, 6, and 12 months after they begin using their HAs. During each contact, HA outcomes (e.g., HA satisfaction) are measured if participants continue using HAs. If participants have abandoned or under-utilized their HAs, their engagement with post-amplification hearing healthcare behaviors (e.g., seeking HAs again) is assessed. The data from the OTC and AUD pathways are then compared.

02

Conditions studied

  • Hearing Loss, Sensorineural
  • Presbycusis

Browse trials for

03

In context

Presbycusis Reclassified

66 studies on the registry are indexed under Presbycusis; 21 are open to participants now.

This study's planned enrollment of 360 is above the median of 60 across 45 interventional studies indexed under Presbycusis.

Browse Presbycusis studies →

Lead sponsor

Yu-Hsiang Wu is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Presbycusis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hearing Loss, Sensorineural. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult-onset, perceived bilateral mild-to-moderate hearing loss
  • no previous hearing aid experience

Exclusion criteria

Exclusion Criteria:

  • Non-native speaker of English
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Active comparator
    AUD (audiologist-based)

    In this group, the audiologist-based fitting will be used to provide prescription hearing aids.

    Device: Audiologist-based fitting

  • Experimental
    OTC (over-the-counter)

    In this group, over-the-counter fitting will be used to provide over-the-counter hearing aids.

    Device: Over-the-counter fitting

Interventions

  • DeviceAudiologist-based fitting

    Description hearing aids will be fitted by audiologists using established procedures.

  • DeviceOver-the-counter fitting

    In this group, over-the-counter hearing aids will be used by subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.

06

What researchers measure

Primary outcomes

  1. Hearing aid satisfaction as measured by the Satisfaction with Amplification in Daily Life (SADL)

    The SADL is a questionnaire designed to measures subject's perceived hearing aid satisfaction. The score ranges from 1 (low satisfaction) to 7 (high satisfaction).

    Time frame: 1-, 6-, and 12-month post-intervention

Secondary outcomes

  1. Overall hearing aid outcome as measured by the International Outcome Inventory for Hearing Aids (IOI-HA)

    The IOI-HA is a questionnaire designed to measures hearing aid outcome across multiple domains, including hearing aid use time and satisfaction. The score ranges from 1 (poor outcome) to 5 (great outcome).

    Time frame: 1-, 6-, and 12-month post-intervention

  2. Aided hearing-specific quality of life as measured by the the Revised Hearing Handicap Inventory (RHHI).

    The RHHI is designed to measure subject's hearing-specific quality of life (i.e., perceived hearing handicap). The score ranges from 0 (no handicap) to 24 (more handicap).

    Time frame: 1-, 6-, and 12-month post-intervention

  3. Hearing aid related issues as measured by the Hearing Aid Issues Survey

    This questionnaire asks participants to report the frequency of occurrence of 15 common device-related issues (e.g., "whistles", "device hurts ear", and ?too loud?) using a 5-point Likert scale. The score ranges from 15 (no issues) to 75 (more issue).

    Time frame: 1-, 6-, and 12-month post-intervention

  4. Hearing aid success as measured by the HA Use Questionnaire

    This instrument has three hearing aid use patterns to choose from: full-time use (whenever hearing aids are needed, score=3), part-time use (occasional use, score=2), and non-use (score=1).

    Time frame: 1-, 6-, and 12-month post-intervention

  5. Engagement with post-amplification hearing healthcare behaviors measured by the Hearing Healthcare Behavior Questionnaire

    This questionnaire measures the participants' engagement with hearing healthcare behaviors after they have abandoned or under-utilized the study HAs (e.g., seeking HAs again). The score ranges from 0 (no engagement) to 1 (full engagement).

    Time frame: 1-, 6-, and 12-month post-intervention

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Brody L, Wu YH, Stangl E. A Comparison of Personal Sound Amplification Products and Hearing Aids in Ecologically Relevant Test Environments. Am J Audiol. 2018 Dec 6;27(4):581-593. doi: 10.1044/2018_AJA-18-0027. PubMed 30458521 ↗
  • Chien W, Lin FR. Prevalence of hearing aid use among older adults in the United States. Arch Intern Med. 2012 Feb 13;172(3):292-3. doi: 10.1001/archinternmed.2011.1408. No abstract available. PubMed 22332170 ↗
  • Gopinath B, Schneider J, Hartley D, Teber E, McMahon CM, Leeder SR, Mitchell P. Incidence and predictors of hearing aid use and ownership among older adults with hearing loss. Ann Epidemiol. 2011 Jul;21(7):497-506. doi: 10.1016/j.annepidem.2011.03.005. Epub 2011 Apr 21. PubMed 21514179 ↗
  • Humes LE, Rogers SE, Quigley TM, Main AK, Kinney DL, Herring C. The Effects of Service-Delivery Model and Purchase Price on Hearing-Aid Outcomes in Older Adults: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Am J Audiol. 2017 Mar 1;26(1):53-79. doi: 10.1044/2017_AJA-16-0111. PubMed 28252160 ↗
  • Lin FR, Niparko JK, Ferrucci L. Hearing loss prevalence in the United States. Arch Intern Med. 2011 Nov 14;171(20):1851-2. doi: 10.1001/archinternmed.2011.506. No abstract available. PubMed 22083573 ↗
  • Nelson PB, Perry TT, Gregan M, VanTasell D. Self-Adjusted Amplification Parameters Produce Large Between-Subject Variability and Preserve Speech Intelligibility. Trends Hear. 2018 Jan-Dec;22:2331216518798264. doi: 10.1177/2331216518798264. PubMed 30191767 ↗
  • Urbanski D, Hernandez H, Oleson J, Wu YH. Toward a New Evidence-Based Fitting Paradigm for Over-the-Counter Hearing Aids. Am J Audiol. 2021 Mar 10;30(1):43-66. doi: 10.1044/2020_AJA-20-00085. Epub 2020 Dec 1. PubMed 33264578 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The proposed research will include data from a total of 360 participants with hearing loss recruited State of Iowa, State of Tennessee and surrounding areas. The final dataset will include self-reported hearing aid outcome data. All datasets and metadata that can be shared will be deposited in the Inter-University Consortium for Political and Social Research (ICPSR).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will be available no later than the publication of the main findings.

Access criteria: The data will be deposited in the Inter-University Consortium for Political and Social Research (ICPSR), and will be available to the public.

09

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms and verification date
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06499805
Lead sponsor
Yu-Hsiang Wu
Responsible party
Yu-Hsiang Wu (Professor, University of Iowa) — Sponsor-investigator
First posted
Jul 12, 2024
Start date
Mar 15, 2025
Primary completion
Apr 1, 2029 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Yu-Hsiang Wu, PhD
Contact
yu-hsiang-wu@uiowa.edu
319-335-8728
Elizabeth Stangl, AuD
Contact
elizabeth-stangl@uiowa.edu
319-335-9758
Yu-Hsiang Wu, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion